uniQure N.V., a biopharmaceutical company, develops adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency. It also develops AMT-060, a gene therapy that is in Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical therapeutic for congestive heart failure; AMT-021, a gene therapy, which has completed Phase I clinical trial for acute intermittent porphyria; AMT-110, a gene therapy that is in Phase I/II clinical trial for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, University of California San Francisco, Bristol-Myers Squibb, and 4D Molecular Therapeutics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
April 3, 2024
RegMed Investors (RMi) Closing Bell: The switch is still flipped
April 2, 2024
RegMed Investors (RMi) - Q4/23 & FY23 Cell and Gene Therapy Earnings Scorecard Results
March 22, 2024
RegMed Investors (RMi) Closing Bell: A question had been asked, are there legs to the sector?
March 15, 2024
RegMed Investors (RMi) Closing Bell: triple witching Friday
March 15, 2024
RegMed Investors’ (RMi) pre-open: a glass half-full or half-empty
March 13, 2024
RegMed Investors (RMi) Closing Bell: drop and give me push-ups, I’ll count until the PPI and jobless claims numbers order
March 12, 2024
RegMed Investors (RMi) Closing Bell: fresh inflation “number” upset daily share pricing response
March 8, 2024
RegMed Investors (RMi) Closing Bell: a drop the mic (microphone) ending for the sector
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors